Priser
Platform
Blog
Om os
Download
Panion & BF Biotech
Panion & BF Biotech
Taiwan Stock Exchange
0

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I PANION & BF BIOTECH MED ENDAVU: Køb Panion & BF Biotech ($1760) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Panion & BF Biotech, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Om

Panion & BF Biotech Inc. is a specialized company in the biotechnology sector. Its primary purpose is to develop, produce, and market pharmaceutical products and biotechnology-related health solutions. The company's expertise lies in the fields of biologics and pharmaceuticals, targeting critical areas such as oncology, vaccines, and rare diseases. Biotech firms like Panion & BF Biotech play significant roles in advancing medical science and improving patient health outcomes. By focusing on innovative therapeutic options and leveraging cutting-edge biotechnology techniques, they contribute to the development of new medicines and treatments that address unmet medical needs. In the financial markets, biotechnology companies are pivotal for their potential impact on healthcare innovation, often drawing interest from investors focused on long-term growth in the health sciences sector. With an emphasis on research and development, Panion & BF Biotech aids in expanding the potential solutions available for complex health challenges globally.

Information

Ticker1760
Land
Taiwan
Hjemmesidepbf.com.tw
SektorSundhed
IndustriBioteknologi

Udbytter

0,69TWD
'21
1,5TWD
'22
2TWD
'23
1,5TWD
'24
1,8TWD
'25
1,8TWD
'26
Ex-udbytte-dato11. jun. 2026
Udbytteafkast2,97%

Analytikerskøn

Baseret på 1 analytiker

Stærkt købKøbHoldSælgStærkt sælg
0%0%100%0%0%